Key terms
About COLL
Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest COLL news
Apr 11
8:20am ET
Collegium Pharmaceutical announces redemption of convertible senior notes
Feb 26
9:37am ET
Collegium Pharmaceutical price target raised to $40 from $37 at Truist
Feb 26
7:16am ET
Truist Financial Sticks to Its Buy Rating for Collegium Pharmaceutical (COLL)
Feb 23
7:31am ET
Analysts Are Bullish on Top Healthcare Stocks: Collegium Pharmaceutical (COLL), Penumbra (PEN)
Feb 23
6:26am ET
H.C. Wainwright Sticks to Their Hold Rating for Collegium Pharmaceutical (COLL)
Feb 23
6:20am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Feb 22
4:15pm ET
Collegium Pharmaceutical Reveals Insightful Earnings Presentation
Feb 02
6:00am ET
Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (COLL) and Hologic (HOLX)
Jan 30
4:55am ET
Collegium Pharmaceutical management to meet virtually with Needham
Jan 25
8:00am ET
Collegium Pharmaceutical management to meet virtually with Needham
No recent press releases are available for COLL
COLL Financials
Key terms
Ad Feedback
COLL Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
COLL Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
